BSBenno Graf Schimmelmann

Benno Graf Schimmelmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benno Graf Schimmelmann has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transition: Herausforderungen und Empfehlungen für Jugendliche und junge Erwachsene mit Schizophrenie

    by Benno Graf Schimmelmann, Alkomiet Hasan

    Zusammenfassung: Hintergrund: Erste akute Episoden oder schwerwiegende rezidivierende Verläufe einer Schizophrenie treten häufig im Transitionsalter auf – dem Übergang zwischen den kinder- und jugendpsychiatrischen sowie den erwachsenenpsychiatrischen Versorgungssystemen. Ziel der Arbeit: Erarbeitung von Herausforderungen und Empfehlungen für die Transition von Patientinnen und Patienten mit Schizophrenie. Material und Methode: Es wurde ein narrativer Review durchgeführt unter Einbezug der aktuellen S3-Leitlinie Schizophrenie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Ergebnisse: Die leitliniengerechte Früherkennung und Behandlung der Schizophrenie stellt bereits unabhängig von der Transition eine Herausforderung dar. Empfehlungen zur Transition betreffen für Kliniken und Niedergelassene Elemente der Erkrankung selbst, der Versorgungs- und Weiterbildungsstruktur und -kultur sowie der Gestaltung und Finanzierung von Behandlungsübergängen. Diskussion: Die aktualisierte 2025 publizierte S3-Leitlinie Schizophrenie enthält zahlreiche Empfehlungen für eine koordinierte Behandlung in der Transitionsphase, hält jedoch in großen Teilen an der Altersgrenze von 18 Jahren fest. Für eine optimale Versorgung im Transitionsalter sind spezialisierte Früherkennungs- und Frühinterventionszentren erforderlich. Eine bidirektionale Flexibilisierung der Altersgrenze zwischen den Versorgungssystemen sowie eine überlappende Behandlung in der Transitionsphase erscheinen in bestimmten Fällen sinnvoll.

  • Schizophrenie

    by Benno G. Schimmelmann, Claudia Mehler-Wex, Christoph Wewetzer

  • Community Treatment Order: Identifying the need for more evidence based justification of its use in first episode psychosis patients

    by Stéphane Morandi, Philippe Golay, Martin Lambert, Benno G Schimmelmann, Patrick D McGorry, Sue M Cotton, Philippe Conus


  • Schizophrenie

    by Benno Schimmelmann, Claudia Mehler-Wex, Christoph Wewetzer

  • Bipolar disorder risk alleles in children with ADHD

    by B. G. Schimmelmann, A. Hinney, A. Scherag, C. Pütter, S. Pechlivanis, S. Cichon, K.-H. Jöckel, S. Schreiber, H. E. Wichmann, Ö. Albayrak, et al.

    Bipolar disorder (BD) and attention deficit/hyperactivity disorder (ADHD) may share common genetic risk factors as indicated by the high co-morbidity of BD and ADHD, their phenotypic overlap especially in pediatric populations, the high heritability of both disorders, and the co-occurrence in families. We therefore examined whether known polygenic BD risk alleles are associated with ADHD. We chose the eight best SNPs of the recent genome-wide association study (GWAS) of BD patients of German ancestry and the nine SNPs from international GWAS meeting a ‘genome-wide significance’ level of α = 5 × 10−8. A GWAS was performed in 495 ADHD children and 1,300 population-based controls using HumanHap550v3 and Human660 W-Quadv1 BeadArrays. We found no significant association of childhood ADHD with single BD risk alleles surviving adjustment for multiple testing. Yet, risk alleles for BD and ADHD were directionally consistent at eight of nine loci with the strongest support for three SNPs in or near NCAN, BRE, and LMAN2L. The polygene analysis for the BP risk alleles at all 14 loci indicated a higher probability of being a BD risk allele carrier in the ADHD cases as compared to the controls. At a moderate power to detect association with ADHD, if true effects were close to estimates from GWAS for BD, our results suggest that the possible contribution of BD risk variants to childhood ADHD risk is considerably lower than for BD. Yet, our findings should encourage researchers to search for common genetic risk factors in BD and childhood ADHD in future studies.


  • Open Access

    Gender differences in first episode psychotic mania

    by Sue M Cotton, Martin Lambert, Michael Berk, Benno G Schimmelmann, Felicity J Butselaar, Patrick D McGorry, Philippe Conus

    The aim of this paper was to delineate the impact of gender on premorbid history, onset, and 18 month outcomes of first episode psychotic mania (FEPM) patients. Medical file audit assessment of 118 (male = 71; female = 47) patients with FEPM aged 15 to 29 years was undertaken on clinical and functional measures. Males with FEPM had increased likelihood of substance use (OR = 13.41, p < .001) and forensic issues (OR = 4.71, p = .008), whereas females were more likely to have history of sexual abuse trauma (OR = 7.12, p = .001). At service entry, males were more likely to be using substances, especially cannabis (OR = 2.15, p = .047), had more severe illness (OR = 1.72, p = .037), and poorer functioning (OR = 0.96, p = .045). During treatment males were more likely to decrease substance use (OR = 5.34, p = .008) and were more likely to be living with family (OR = 4.30, p = .009). There were no gender differences in age of onset, psychopathology or functioning at discharge. Clinically meaningful gender differences in FEPM were driven by risk factors possibly associated with poor outcome. For males, substance use might be associated with poorer clinical presentation and functioning. In females with FEPM, the impact of sexual trauma on illness course warrants further consideration.


  • Open Access

    The Significance of At-Risk Symptoms for Psychosis in Children and Adolescents

    by Benno Graf Schimmelmann, Petra Walger, Frauke Schultze-Lutter

    The early detection and treatment of people at risk for psychosis is currently regarded as a promising strategy in fighting the devastating consequences of psychotic disorders. Currently, the 2 most broadly used sets of at-risk criteria, that is, ultra-high risk (UHR) and basic symptom criteria, were developed mainly in adult samples. We review the data regarding the presence and relevance of at-risk symptoms for psychosis in children and adolescents. The few existing studies suggest that attenuated psychotic symptoms (APS) and brief limited intermittent psychotic symptoms (BLIPS) do have some clinical relevance in young adolescents from the general population. Nevertheless, their differentiation from atypical psychotic symptoms or an emerging schizotypal personality disorder, as well as their stability and predictive accuracy for psychosis, are still unclear. Further, standard interviews for UHR criteria do not define a minimum age for the assessment of APS and BLIPS or guidelines as to when and how to include information from parents. APS and basic symptoms may be predictive of conversion to psychosis in help-seeking young adolescents. Nevertheless, the rate and timing, and thus the required observation time, need further study. Moreover, no study has yet addressed the issue of how to treat children and adolescents presenting with at-risk symptoms and criteria. Further research is urgently needed to examine if current at-risk criteria and approaches have to be tailored to the special needs of children and adolescents. A preliminary rationale for how to deal with at-risk symptoms for psychosis in clinical practice is provided.


  • Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis

    by B.G. Schimmelmann, P. Conus, S. Cotton, S. Kupferschmid, P.D. McGorry, M. Lambert

    Previous studies on the impact of cannabis use disorders (CU) on outcome in psychosis were predominantly based on non representative samples, often have not controlled for confounders and rarely focused on adolescent patients. Thus, the aims of the present study were to assess: (i) prevalence of CU; (ii) baseline and pretreatment differences between CU and those without CU (NCU); (iii) the impact of baseline and course of CU on 18-month outcomes in a representative cohort of adolescents with early onset first episode psychosis (EOP). The sample comprised 99 adolescents (age 14 to 18) with EOP (onset age 14 to 17), admitted to the Early Psychosis Prevention and Intervention Centre in Australia. Data were collected from medical files using a standardized questionnaire. Prevalence of lifetime CU was 65.7%, of current CU at baseline 53.5%, and of persistent CU throughout treatment 26.3%. Baseline CU compared to NCU had significantly higher illness-severity, lower psychosocial functioning, less insight, lower premorbid functioning and longer duration of untreated psychosis. Compared to all other groups, only persistent CU was linked to worse outcomes and more service disengagement. Effect sizes were medium controlling for relevant confounders. Medication non-adherence did not explain the association between persistent CU and worse outcome. Baseline CU was associated with worse baseline characteristics, but only persistent CU was linked with worse outcome. About half of those with baseline CU reduced cannabis during treatment. For these, effectively treating the psychotic disorder may already be beneficial. However, future research is necessary on the reasons for persistent CU in EOP and its treatment.


  • Open Access

    Addendum: Genome-wide association study in German patients with attention deficit/hyperactivity disorder

    by Anke Hinney, André Scherag, Ivonne Jarick, Özgür Albayrak, Carolin Pütter, Sonali Pechlivanis, Maria R. Dauvermann, Sebastian Beck, Heike Weber, Susann Scherag, et al.